Metabolic Diseases
Metabolic Diseases
Search
Lung Diseases
Lung Diseases
Skin Diseases
Skin Diseases
Heart Diseases
Heart Diseases
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
Retinal Diseases
Retinal Diseases
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Tackling care gaps in respiratory diseases in Alberta
Tackling care gaps in respiratory diseases in Alberta
New health projects empower Indigenous communities to address chronic diseases
New health projects empower Indigenous communities to address chronic diseases
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot
• Boehringer Ingelheim Animal Health Canada Inc. launches a unique vaccine combination that protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv) in one shot
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim - Value Through Innovation
Science Focus
Science and Innovation - Human Health Innovation - Science Focus
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Partnering-In-CARDIOMETABOLIC
CardioMetabolic-infographic-Update-2021
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction
JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.